Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC7861 | HC 067047 |
| Potent and selective TRPV4 antagonist. Reversibly inhibits currents through mouse, human and rat TRPV4 orthologs (IC50 values are 17, 48 and 133 nM respectively). Also inhibits the endogenous TRPV4-mediated response to 4α-PDH (IC50 = 22 nM). Selective for TRPV4 over TRPV1, TRPV2, TRPV3 and TRPM8 channels. | |
| BCC7868 | Bisindolylmaleimide II |
| Potent, ATP-competitive protein kinase C (PKC) inhibitor (IC50 = 0.01 μM). Displays selectivity for PKC over protein kinase A (PKA) and phosphorylase kinase (PK) (IC50 values are 0.75 and 2μM for PK and PKA respectively). Also displays potent, noncompetitive antagonism at nicotinic cholinergic receptors (IC50 ~ 0.03 μM for inhibition of catecholamine secretion in nicotine-stimulated PC-12 cells). | |
| BCC7869 | LY 2087101 |
| Allosteric potentiator of α7, α4β2 and α4β4 nAChRs; displays selectivity against α3β4 nAChRs. Thought to potentiate agonist-evoked α7 responses by binding within the nAChR transmembrane region. | |
| BCC7872 | NS 5806 |
| KV4.3 channel activator; mediates the transient outward K+ current (Ito). Increases IKv4.3 peak current amplitude in CHO-K1 cells expressing KV4.3 and KChIP2 (EC50 = 5.3 μM). Inhibits KV1.4-mediated currents independently of KChIP2. Also slows the decay of KV4.2 and KV4.3 currents in the presence of KChIP2. | |
| BCC7873 | PIT 1 |
| Selective PIP3 antagonist. Blocks the binding of PIP3 to the pleckstrin homology (PH) domain of Akt (IC50 = 31.03 μM). Inhibits cancer cell survival and induces apoptosis by inhibition of PIP3-dependent PI 3-kinase/Akt signaling. Exhibits antitumor activity in vivo. | |
| BCC7874 | KS 176 |
| Selective inhibitor of the breast cancer resistance protein (BCRP) multidrug transporter (IC50 values are 0.59 and 1.39 μM in Pheo A and Hoechst 33342 assays respectively). Displays no inhibitory activity against P-gp or MRP1. | |
| BCC7878 | AS 1269574 |
| GPR119 receptor agonist (EC50 = 2.5 μM in HEK293 cells expressing human GPR119). Enhances insulin secretion stimulated by glucose in vivo. Stimulates proglucagon gene promoter actvity. Orally available. | |
| BCC7880 | SC 26196 |
| Selective Δ6 desaturase inhibitor (IC50 = 0.2 μM in vitro). Displays selectivity over Δ5 and Δ9 desaturases (IC50 values are >200 μM in vitro). Exhibits anti-inflammatory properties in a mouse edema model. | |
